Dysesthesia: A New Signal for Retatrutide The TRIUMPH-4 Phase 3 trial revealed an unexpected finding: dysesthesia (abnormal touch sensations where normal sensations feel unusual or painful) in 20.9% of participants on 12 mg and 8.8% on 9 mg, compared to 0.7% on placebo (BioSpace, Dec 2025)
TB-500 is widely studied for its effects on cell migration, cytoskeletal organization, and tissue remodeling, while KPV has attracted significant interest for its role in immune regulation, inflammatory signaling, and epithelial barrier biology
Which is easy if you're dosing at bedtime, since you'll be asleep
Phase Moderate range Daily dose 40-80 mcg/day Frequency Once daily Notes Diminishing returns commonly reported above ~50-60 mcg/day
And while on the topic of the antioxidant glutathione, Dr
Supplied as a high-purity lyophilized peptide blend with full COA traceability